Background: A dolutegravir plus darunavir/cobicistat regimen has been used as a simplified option in heavily treatment-experienced people with HIV (PWH). We report on long-term results of this regimen as assessed by treatment discontinuation (TD) for any reason.
Methods: This was a retrospective, observational, multicentre study. PWH started on dolutegravir plus darunavir/cobicistat from 1 December 2015 to 31 December 2022 were included. The primary endpoint was the rate of TD for any reason. Survival analysis with the Kaplan-Meier estimator was used to assess the probability of TD over time. Multiple Cox regression was used to estimate the probability of TD at 1 year following regimen initiation.
Results: Three hundred and twenty-seven subjects were included. At baseline, 63.6% of individuals had HIV RNA of <50 copies/mL. Primary resistance-associated mutations for NRTIs, NNRTIs, PIs and integrase inhibitors were documented in 88.0%, 70.0%, 24.5% and 6.6%, respectively. Median follow-up was 4 years (IQR 3.3-6.9). Probability of TD was 8.3%, 13.0%, 18.0%, 22.0%, 25.0%, 30.0% and 35.0% after 1, 2, 3, 4, 5, 6 and 7 years of treatment, respectively. TD occurred in 83 subjects, largely due to death (n = 20), simplification (n = 13), toxicity (n = 11), intolerance (n = 9), drug interactions (n = 10) and virological failure (n = 7). At Cox regression analysis, factors associated with a higher probability of TD over time were baseline HIV RNA of >50 copies/mL (HR = 2.14, 95% CI 1.20-3.81; P = 0.01) and the presence of PI or integrase strand transfer inhibitor resistance mutations (HR = 5.48, 95% CI 2.42-12.4; P < 0.001).
Conclusions: Dolutegravir plus darunavir/cobicistat is a durable combination in heavily treatment-experienced PWH. Those who were viraemic at the time of switch were more likely to discontinue, although most reasons for TD were other than virological failure.
© The Author(s) 2025. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.